A Phase I Clinical Trial to Study the Toxicity, Pharmacokinetics, and Efficacy of Human Monoclonal Antibody, F105, for Treating Human Immunodeficiency Virus Infection.

Inclusion Criteria Concurrent Medication: PART B ONLY. Allowed: * Concomitant AZT or other antiretroviral drugs if patient is on a stable dose of such therapy within 3 months prior to study entry. Patients must have: * Documented HIV-1 infection. * CD4 count 200 - 500 cells/mm3 (Part A) or \<= 400 cells/mm3 (Part B, per amendment). * No diagnosis of AIDS (Part A only, per amendment). * Life expectancy of at least 6 months. Part B patients only (per amendment): * Primary (viral) isolates sensitive to F105 antibody using the yield reduction assay currently under development by ACTG, determined within 15-90 days prior to study entry. * Plasma viremia by qualitative plasma culture. * NO active opportunistic infection within 6 weeks prior to drawing of first isolate. * NO AIDS-related malignancy other than minimal Kaposi's sarcoma. Prior Medication: Allowed: * Prior AZT or other nucleoside antiviral agents. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Evidence of active renal disease as manifested by sediment containing red or white cell casts. Concurrent Treatment: Excluded: * Red cell transfusions administered to maintain hemoglobin at acceptable level or alleviate symptoms of anemia. Prior Medication: Excluded within 6 weeks prior to study entry: * Intravenous gamma globulin. * Chemotherapy. * Corticosteroids. * Other experimental therapy. EXCLUDED IN ALL PATIENTS: * Immunosuppressive treatments, cytokine therapy, or biologic response modifiers not included in this study, including interferons or adjuvant treatment for chronic and severe fungal infections such as cryptococcal meningitis. * Intravenous gamma globulin. * Chemotherapy. * Corticosteroids. * Other experimental therapy. * G-CSF, GM-CSF, or erythropoietin. EXCLUDED IN PART A ONLY: * Drugs known to enhance or block metabolism of other drugs. EXCLUDED IN PART B ONLY: * AZT or other antiretroviral drugs IF INITIATED during or within 1 month after completion of study. Active alcohol or drug abuse that may compromise ability to comply with study requirements.